Literature DB >> 16265593

Different properties of four molecular forms of protein kinase CK2 from Saccharomyces cerevisiae.

Katarzyna Domańska1, Rafał Zieliński, Konrad Kubiński, Ewa Sajnaga, Maciej Masłyk, Maria Bretner, Ryszard Szyszka.   

Abstract

CK2 is a pleiotropic constitutively active serine/threonine protein kinase composed of two catalytic alpha- and two regulatory beta-subunits, whose regulation is still not well understood. It seems to play an essential role in regulation of many cellular processes. Four active forms of CK2, composed of alphaalpha'betabeta', alpha(2)betabeta', alpha'(2)betabeta', and a free alpha'-subunit were isolated from wild-type yeast and strains containing a single deletion of the catalytic subunit. Each species exhibits properties typical for CK2, but they differ in substrate specificity and sensitivity to inhibitors. This suggests that each CK2 isomer may regulate different process or may differ in the way of its regulation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16265593

Source DB:  PubMed          Journal:  Acta Biochim Pol        ISSN: 0001-527X            Impact factor:   2.149


  10 in total

1.  Interactions between subunits of protein kinase CK2 and their protein substrates influences its sensitivity to specific inhibitors.

Authors:  Monika Janeczko; Maciej Masłyk; Ryszard Szyszka; Andrea Baier
Journal:  Mol Cell Biochem       Date:  2011-07-14       Impact factor: 3.396

2.  Sgt1 dimerization is negatively regulated by protein kinase CK2-mediated phosphorylation at Ser361.

Authors:  Parmil K Bansal; Ashutosh Mishra; Anthony A High; Rashid Abdulle; Katsumi Kitagawa
Journal:  J Biol Chem       Date:  2009-04-27       Impact factor: 5.157

3.  Yeast holoenzyme of protein kinase CK2 requires both beta and beta' regulatory subunits for its activity.

Authors:  Konrad Kubiński; Katarzyna Domańska; Ewa Sajnaga; Elzbieta Mazur; Rafał Zieliński; Ryszard Szyszka
Journal:  Mol Cell Biochem       Date:  2006-08-24       Impact factor: 3.396

4.  Suppression of Ycf1p function by Cka1p-dependent phosphorylation is attenuated in response to salt stress.

Authors:  Kerry A Pickin; Nkiruka Ezenwajiaku; Holly Overcash; Manish Sethi; Marc R Knecht; Christian M Paumi
Journal:  FEMS Yeast Res       Date:  2010-08-31       Impact factor: 2.796

5.  A specific catalytic subunit isoform of protein kinase CK2 is required for phosphorylation of the repressor Nrg1 in Saccharomyces cerevisiae.

Authors:  Cristin D Berkey; Marian Carlson
Journal:  Curr Genet       Date:  2006-04-11       Impact factor: 3.886

Review 6.  CK2 and the Hallmarks of Cancer.

Authors:  May-Britt Firnau; Angela Brieger
Journal:  Biomedicines       Date:  2022-08-16

7.  Yeast surviving factor Svf1 as a new interacting partner, regulator and in vitro substrate of protein kinase CK2.

Authors:  Maciej Masłyk; Elzbieta Kochanowicz; Rafał Zieliński; Konrad Kubiński; Ulf Hellman; Ryszard Szyszka
Journal:  Mol Cell Biochem       Date:  2008-02-12       Impact factor: 3.396

8.  CX-4945: the protein kinase CK2 inhibitor and anti-cancer drug shows anti-fungal activity.

Authors:  Maciej Masłyk; Monika Janeczko; Aleksandra Martyna; Konrad Kubiński
Journal:  Mol Cell Biochem       Date:  2017-05-13       Impact factor: 3.396

9.  Identification and Phenotypic Characterization of Hsp90 Phosphorylation Sites That Modulate Virulence Traits in the Major Human Fungal Pathogen Candida albicans.

Authors:  Leenah Alaalm; Julia L Crunden; Mark Butcher; Ulrike Obst; Ryann Whealy; Carolyn E Williamson; Heath E O'Brien; Christiane Schaffitzel; Gordon Ramage; James Spencer; Stephanie Diezmann
Journal:  Front Cell Infect Microbiol       Date:  2021-08-27       Impact factor: 5.293

10.  A representative of arylcyanomethylenequinone oximes effectively inhibits growth and formation of hyphae in Candida albicans and influences the activity of protein kinases in vitro.

Authors:  Maciej Masłyk; Monika Janeczko; Oleg M Demchuk; Anna Boguszewska-Czubara; Hieronim Golczyk; Anna Sierosławska; Anna Rymuszka; Aleksandra Martyna; Konrad Kubiński
Journal:  Saudi Pharm J       Date:  2017-12-05       Impact factor: 4.330

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.